Cost considerations of the new fixed combinations for glaucoma medical therapy

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 3, 2005, Pages 251-254

  Ventura, Marcelo Palis ^a,b,c   Saheb, N E ^a   Solari, H P ^a   Saraiva, V S ^a   Vianna, R N G ^b   Burnier Jr , M N ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c Lyman Duff Building ^*  (Canada)

Author keywords

Costs; Glaucoma; Medication

Indexed keywords

ANTIGLAUCOMA AGENT; COMBIGAN; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST PLUS TIMOLOL MALEATE; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; BRIMONIDINE; DORZOLAMIDE TIMOLOL COMBINATION; DORZOLAMIDE-TIMOLOL COMBINATION; LATANOPROST; PROSTAGLANDIN F; QUINOXALINE DERIVATIVE; SULFONAMIDE; THIOPHENE DERIVATIVE; TIMOLOL;

ACCURACY; ARTICLE; CANADA; DRUG COST; GLAUCOMA; PHARMACY; DRUG COMBINATION; ECONOMICS; HUMAN; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTIHYPERTENSIVE AGENTS; CANADA; DRUG COMBINATIONS; GLAUCOMA; HUMANS; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 23844483706     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00641.x     Document Type: Article

References (21)

1. Fraser S, Bunce C, Wormald R (1999) Risk factors for late presentation in chronic glaucoma. Investigative Ophthalmology and Visual Science, 40, 1-7.
2. American Academy of Ophthalmology (2000) Preferred practice pattern: primary open-angle glaucoma. San Francisco, CA: American Academy of Ophthalmology.
3. Feldman RM (2004) An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opinion on Pharmacotherapy, 5, 909-921.
4. Shin DH, Feldman RM, Sheu W (2004) Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Fixed combination latanoprost/timolol study group. Ophthalmology, 111, 276-282.
5. Weinreb RN (1992) Compliance with medical treatment of glaucoma. Journal of Glaucoma, 1, 134-136.
6. Ball SF, Schneider E (1992) Cost of β-adrenergic receptor blocking agents for ocular hypertension. Archives of Ophthalmology, 110, 654-657.
7. Platt R, Reardon G, Mozaffari E (2004) Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. American Journal of Ophthalmology, 137, S17-S23.
8. Stewart WC, Sine C, Gate E, Minno GE, Hunt HH (1997) Daily cost of beta-adrenergic blocker therapy. Archives of Ophthalmology, 115, 853-856.
9. Fiscella RG, Geller JL, Gryz LL, Wilensky, Viana M (1999) Cost consideration of medical therapy for glaucoma. American Journal of Ophthalmology, 128, 426-433.
10. Prata JA Jr, Prata JA (2004) Drop volume and cost of treatment with generic 0.5% timolol maleate preparations. Arquivos Brasileiros de Oftalmologia, 67, 419-422.
11. Van Santvliet L, Ludwig A (2004) Determinants of eye drop size. Survey of Ophthalmology, 49, 197-213.
12. Fechtner RD, Realini T (2004) Fixed combinations of topical glaucoma medications. Current Opinion in Ophthalmology, 15, 132-135.
13. Konstas AGP, Kozobolis VP, Lallos N, Christodoulakis, Stewart JA, Stewart WC (2004) Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye, 18, 1264-1269.
14. Sall KN, Greff LJ, Johnson-Patt LR et al. (2003) Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol. Six-month comparison of efficacy and tolerability. Ophthalmology, 110, 615-624.
15. Garcia-Sanchez J, Rouland JF, Spiegel D, Pajic B, Cunliffe I, Traverso C, Landry J (2004) A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe. British Journal of Ophthalmology, 88, 877-883.
16. Craven ER, Sherwood MB, Dubiner HB (2004) Twelve-month randomized comparison of fixed combination brimonidine 0.2%/timolol 0.5% with each component as monotherapy. American Academy of Ophthalmology Annual Meeting Abstracts PO058.
17. Dogan AS, Orhan M, Soylemezoglu F, Irkec M, Bozkurt B (2004) Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clinical and Experimental Ophthalmology, 32, 62-66.
18. Lavin MJ, Wormald RP, Migdal CS, Hitchngs RA (1990) The influence of prior therapy on the success of trabeculectomy. Archives of Ophthalmology, 108, 1543-1548.
19. Quigley HA (1996) Number of people with glaucoma worldwide. British Journal of Ophthalmology, 80, 389-393.
20. Strutton DR, Walt JG (2004) Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. Journal of Glaucoma, 13, 221-226.
21. Walland MJ (2004) Glaucoma treatment in Australia: changing patterns of therapy 1994-2003. Clinical and Experimental Ophthalmology, 32, 590-596.